Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384215
Status:
COMPLETED
Last Update Posted:
2011-01-11
First Post:
2006-10-04
Brief Title:
Insulin Glargine rDNA Origin Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Insulin Glargine rDNA Origin Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin a Randomized Open Parallel Study
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy Glycemic control hypoglycemia weight lipid profiles quality of life and cost will be studied given a comprehensive set of data that may help future treatment decisions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None